Alliance Pharma plc

AIM:APH Stock Report

Market Cap: UK£350.3m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Alliance Pharma Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Nick Sedgwick

Chief executive officer

UK£457.7k

Total compensation

CEO salary percentage51.53%
CEO tenure1yr
CEO ownershipn/a
Management average tenure7.7yrs
Board average tenure1.5yrs

Recent management updates

Recent updates

Analysis Article • Sep 10

Investors Aren't Entirely Convinced By Alliance Pharma plc's (LON:APH) Revenues

Alliance Pharma plc's ( LON:APH ) price-to-sales (or "P/S") ratio of 1.2x might make it look like a strong buy right...
Analysis Article • Jun 21

Is Alliance Pharma (LON:APH) A Risky Investment?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analysis Article • Feb 23

Not Many Are Piling Into Alliance Pharma plc (LON:APH) Just Yet

You may think that with a price-to-sales (or "P/S") ratio of 1.4x Alliance Pharma plc ( LON:APH ) is definitely a stock...
Analysis Article • Nov 21

Estimating The Intrinsic Value Of Alliance Pharma plc (LON:APH)

Key Insights Alliance Pharma's estimated fair value is UK£0.33 based on Dividend Discount Model With UK£0.38 share...
Analysis Article • May 26

We Think Alliance Pharma (LON:APH) Is Taking Some Risk With Its Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analysis Article • Mar 24

Alliance Pharma plc Just Missed Earnings - But Analysts Have Updated Their Models

It's shaping up to be a tough period for Alliance Pharma plc ( LON:APH ), which a week ago released some disappointing...
Analysis Article • Sep 30

We Think Alliance Pharma (LON:APH) Can Stay On Top Of Its Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • May 28

An Intrinsic Calculation For Alliance Pharma plc (LON:APH) Suggests It's 41% Undervalued

Today we will run through one way of estimating the intrinsic value of Alliance Pharma plc ( LON:APH ) by taking the...
Analysis Article • Mar 30

Alliance Pharma (LON:APH) Has A Pretty Healthy Balance Sheet

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Analysis Article • Dec 24

Did Alliance Pharma's (LON:APH) Share Price Deserve to Gain 81%?

Stock pickers are generally looking for stocks that will outperform the broader market. And in our experience, buying...
Analysis Article • Nov 19

Do Fundamentals Have Any Role To Play In Driving Alliance Pharma plc's (LON:APH) Stock Up Recently?

Alliance Pharma's (LON:APH) stock up by 2.2% over the past three months. As most would know, long-term fundamentals...

CEO Compensation Analysis

How has Nick Sedgwick's remuneration changed compared to Alliance Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024UK£458kUK£236k

-UK£11m

Compensation vs Market: Nick's total compensation ($USD609.05K) is below average for companies of similar size in the UK market ($USD1.13M).

Compensation vs Earnings: Insufficient data to compare Nick's compensation with company performance.

CEO

Nick Sedgwick (52 yo)

1yr
Tenure
UK£457,710
Compensation

Mr. Nicholas John Sedgwick, also known as Nick, is Chief Executive Officer and Director of Alliance Pharma plc from May 13, 2024. Sedgwick brings thirty years of consumer health experience across European,...

Leadership Team

NamePositionTenureCompensationOwnership
Nicholas Sedgwick
CEO & Director1yrUK£457.71kno data
Andrew Franklin
CFO & Executive Director9.7yrsUK£367.15k0.036%
£ 124.8k
Cora McCallum
Head of Investor Relations & Corporate Communicationsno datano datano data
Christodoulos Chrysanthou
Group General Counsel & Company Secretary7.7yrsno datano data
Julie Skinner
Chief People Officer2.3yrsno datano data
Chris Delafield
Global Marketing Head of Kelo-Cote8.3yrsno datano data
Rhodri Smith
Head of Sourcingno datano datano data
7.7yrs
Average Tenure

Experienced Management: APH's management team is seasoned and experienced (7.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Nicholas Sedgwick
CEO & Director1yrUK£457.71kno data
Andrew Franklin
CFO & Executive Director9.7yrsUK£367.15k0.036%
£ 124.8k
Martin Sutherland
Independent Non-Executive Director2.3yrsUK£55.84kno data
Richard Crispin Jones
Senior Independent Non-Executive Director6.3yrsUK£59.95k0.013%
£ 44.0k
Camillo Pane
Independent Non Executive Chair1.3yrsUK£106.15kno data
Kristof Neirynck
Independent Non-Executive Director3.4yrsUK£55.55kno data
Richard McKenzie
Independent Non-Executive Director1.5yrsUK£50.80k0.0043%
£ 14.9k
Eva-Lotta Sjostedt
Independent Non-Executive Director1.5yrsUK£51.05kno data
Martin Camilo
Member of Supervisory Board1.3yrsno datano data
1.5yrs
Average Tenure
55yo
Average Age

Experienced Board: APH's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/13 22:24
End of Day Share Price 2025/05/13 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alliance Pharma plc is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Samuel EnglandBerenberg
Julie SimmondsCanaccord Genuity
Mark BrewerCavendish